

## PRESS RELEASE

# Lysogene Reports its Cash Position as of 30 June 2022

- Cash and cash equivalents of €7.7 million<sup>1</sup> as of 30 June 2022

Paris, France — 21 July 2022 at 08:00 am CET — Lysogene (FROO13233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today reports its cash position of €7.7 million<sup>1</sup> as of 30 June 2022 (compared to €10.7 million as of 31 March 2022). The company's cash runway runs until January 2023.

**Karen Aiach, Chairman and CEO** of Lysogene said: *"We are working hard and making progress to pursue all possible options for extending our cash runway in this challenging fundraising environment for biotech companies. The second half of the year will be critical, and we hope that we will be able to leverage the recent positive clinical news flow to refinance."*

### About Lysogene

Lysogene is a gene therapy Company focused on the treatment of orphan diseases of the central nervous system (CNS). The Company has built a unique capability to enable delivery of gene therapies to the CNS to treat lysosomal diseases and other disorders of the CNS. A phase 2/3 clinical trial in MPS IIIA is ongoing. An adaptive clinical trial in GM1 gangliosidosis is also ongoing. Lysogene is also developing an innovative AAV gene therapy approach for the treatment of Fragile X syndrome, a genetic disease related to autism. The Company also entered into an exclusive worldwide license agreement with Yeda, the commercial arm of the Weizmann Institute of Science, for a novel gene therapy candidate for neuronopathic Gaucher disease and Parkinson disease with GBA1 mutations. [www.lysogene.com](http://www.lysogene.com).

### Forward Looking Statement

This press release may contain certain forward-looking statements, especially on the Company's progress of its clinical trials and cash runway. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice, (ii) factors beyond the

---

<sup>1</sup> Unaudited figure

Company's control, (iii) clinical trial results, (iv) increased manufacturing costs, (v) potential claims on its products. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "objective", "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. A further list and description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the French Autorité des Marchés Financiers, including in the 2021 universal registration document, registered with the French Markets Authorities on April 19, 2022, and future filings and reports by the Company. Furthermore, these forward-looking statements are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. If the Company updates one or more forward-looking statements, no inference should be drawn that it will or will not make additional updates with respect to those or other forward-looking statements.

This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.

### **Contacts**

Stéphane Durant des Aulnois

Chief Financial Officer

[stephane.durant-des-aulnois@lysogene.com](mailto:stephane.durant-des-aulnois@lysogene.com)

+ 33 1 41 43 03 99